Romosozumab zur Verbesserung der Knochenmineraldichte und -architektur bei chronischem SCI (Chronic Romo)
Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD).
The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur <1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Persons with chronic spinal cord injury (SCI) have markedly reduced bone mass and the loss of skeletal architectural integrity, which predisposes them to low-impact fractures. Currently, there is no practical treatment to reverse the severe bone loss in persons with chronic SCI. In the proposed study, a dual pharmacological intervention will be tested to improve bone health. Restoration of bone mass below the level of injury would be expected to reduce the morbidity associated with fractures and permit safer participation in upright activities. Quality of life would be substantially improved because of the ability to engage more securely in activities of daily living and to integrate into the community. Despite the depressed skeletal activity below the level of lesion in persons with chronic SCI, net bone loss occurs because resorption exceeds formation, with a difference between these rates in those with SCI being greater than that observed in the able-bodied population. Thus, it would be anticipated to be of value in persons with chronic SCI to increase bone turnover with the objective to increase bone formation over that of bone resorption. In a preclinical study that administered an anti-sclerostin antibody to rats 12 weeks after complete spinal cord transection bone, mineral density (BMD) was almost fully restored at the distal femoral metaphysis, with improved bone structure, and mechanical strength; in contrast, vehicle-treated animals after complete spinal transection had a marked reduction in distal femoral metaphysis BMD and a deterioration in bone structure and mechanical strength. When used to treat postmenopausal osteoporosis, romosozumab, a human monoclonal anti-sclerostin antibody, was more effective to increase bone mineral density (BMD) and to reduce fracture than any other anti-resorptive or bone-anabolic agent, and this effect was also evident for the appendicular skeleton, which is the site in individuals with chronic SCI of greatest bone loss and most frequent fracture. Because of the absence of clinical options available for the treatment of osteoporosis in individuals with chronic paralysis, the investigators have proposed to test an antagonist of sclerostin, which is a potent bone anabolic agent with proven efficacy in treating women with postmenopausal osteoporosis, to improve bone mass and reduce fragility fractures.
Thirty-nine male and female subjects with chronic, motor-complete or incomplete SCI (>3 years post injury, American Spinal Injury Association Impairment Scale A & B) between the ages of 18 and 55 years old (for females) or 65 years old (for males) who have aBMD at the distal femur at the distal femur <1.0 g/cm2 will be recruited for participation in a randomized, double-blind, placebo-controlled, parallel group clinical trial. The outcome measures of the proposed study are bone mineral density (BMD) by peripheral quantitative computed tomography (pQCT) and dual energy x-ray absorptiometry (DXA), and biochemical markers of bone resorption and formation. This prospective, randomized, placebo controlled clinical trial will take place at the James J. Peters VA Medical Center (JJPVAMC) and Kessler Institute for Rehabilitation (KIR) (each facility will perform patient enrollment and study procedures).
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
New Jersey
-
West Orange, New Jersey, Vereinigte Staaten, 07052
- Kessler Institute for Rehabilitation
-
-
New York
-
The Bronx, New York, Vereinigte Staaten, 10468-3904
- James J. Peters VA Medical Center, Bronx, NY
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Motor-complete or incomplete spinal cord injury (SCI) [all levels of lesion] classified using International Standards for Neurological Classification for Spinal Cord Injury (ISNCSCI) impairment scale] as ISNCSCI score A-C
- Duration of injury >3 years
- Males (18-65 years old) and females (premenopausal, between the ages of 18 and 55 years old).
- Areal bone mineral density (aBMD) at the distal femur <1.0 g/cm2 (determined at screening)
Exclusion Criteria:
- Long-bone fracture of the leg within the past year
- History of prior bone disease (Paget's hyperparathyroidism, etc.)
- Active and/or history of coronary heart disease or stroke within the past year
- Postmenopausal women
- Men with known hypogonadism prior to spinal cord injury (SCI)
- Anabolic therapy longer than six months duration after spinal cord injury (SCI)
- Glucocorticoid administration longer than three months duration within the last year, and/or prescribed moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute spinal cord injury (SCI)
- Endocrinopathies (hyperthyroidism, Cushing's disease or syndrome, etc.)
- Severe underlying chronic disease (e.g., COPD, end-stage heart disease, chronic renal failure)
- Heterotopic ossification (HO) of the knee region (the distal femoral epiphysis is the primary endpoint); HO to any other boney region will not prevent study participation as long as contraindicated medications have not been prescribed)
- Chronic alcohol abuse
- Hypocalcemia
- Pregnancy
- Prescribed a bisphosphonate for HO, or prescribed any other agent to treat osteoporosis other than calcium and vitamin D
- Electrical stimulation of the lower extremities
- Current diagnosis of cancer or history of cancer
- Osteosarcoma
- Life expectancy less than 5 years
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Romosozumab Treatment (baseline to month 11)
Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months. |
39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
Andere Namen:
|
|
Placebo-Komparator: Placebo (baseline to month 12)
Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group. |
Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
Andere Namen:
|
|
Aktiver Komparator: Denosumab (month 12 to month 24)
Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI). |
Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in vBMD at the Distal Femur, measured by pQCT after 12 months of romosozumab treatment
Zeitfenster: Baseline (0), Month 6, Month 12
|
Percent change of volumetric BMD (vBMD) milligrams per cubic centimeter (mg/cm^3)at the distal femur, measured by peripheral quantitative computed tomography (pQCT) (slice thickness 2.4mm, default voxel size of 0.5mm), with 12 months of romosozumab therapy. vBMD measurements will be taken at baseline, month 6 and month 12. |
Baseline (0), Month 6, Month 12
|
|
Change in vBMD at the distal femur after an additional 12 months of denosumab treatment
Zeitfenster: Month 18, Month 24
|
Percent change of Integral vBMD (mg/cm^3)at the distal femur, measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm), after additional 12 months of denosumab therapy. vBMD measurements will be taken by pQCT at months 18 and 24. |
Month 18, Month 24
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Additional variables by pQCT - vBMD Proximal Tibia
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in proximal tibia vBMD (mg/cm^3), measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - tBMD Distal Femur
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in distal femur trabecular BMD (tBMD) (mg/cm^3) will be measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - tBMD Proximal Tibia
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in proximal tibia tBMD (mg/cm^3) will be measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - cortical BMD of the tibia (38% of the tibial length)
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in cortical vBMD (mg/cm^3) will be measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - Distal Tibia Microarchitecture
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to measure trabecular microarchitecture [trabecular separation (Tb.Sp), bone volume fraction (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th)] at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by DXA - aBMD Distal Femur and Proximal Tibia (i.e. knee)
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change of regional BMD of the knee (e.g., distal femoral and proximal tibial epiphyses using the orthopedic knee software commercially available from GE Lunar). The starting point to acquire the knee is set on the tibia approximately 10 cm distal from the edge of the patella, with the scan field extending to the epiphysis and metaphysis of the distal femur. aBMD measurements will be taken at Baseline (0), Month 6, Month 12, Month 18, Month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by DXA - aBMD Hip
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in aBMD of the hips (total dual dip and subregions) will be measured at Baseline (0), Month 6, Month 12, Month 18, Month 24. Accepted values for T-score and Z-scores of the hip will be utilized. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Biomarkers for Bone Resorption (CTx)
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Change in levels of the circulating biochemical markers of bone resorption and formation before (baseline) and after initiating romosozumab therapy (1, 3, 6, and 12 months), and then after 6 and 12 months of denosumab administration will be measured. Levels of serum C-telopeptide (CTx) (ABclonal. 86 Cummings Park, Woburn, MA) will be measured as the biomarker of bone resorption. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Biomarkers for Bone Formation (osteocalcin, alkaline phosphatase, P1NP)
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Change in levels of the circulating biochemical markers of bone resorption and formation before (baseline) and after initiating romosozumab therapy (1, 3, 6, and 12 months), and then after 6 and 12 months of denosumab administration will be measured. Serum osteocalcin (Alpco Diagnostics, Salem, NH), bone alkaline phosphatase (MyBiosource, Inc., San Diego, CA) and propeptide of type 1 procollagen (P1NP) (MyBiosource, Inc., San Diego, CA) will be measured as biomarkers of bone formation. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Serum total and ionized calcium concentration, 24-hour urine calcium, 25 OH-vitamin D level (DiaSorin Inc. Stillwater, MN), 1,25 (OH)2-vitamin D level (Quest Diagnostics), and intact PTH level (ALPCO Diagnostics, Salem, NH) will be measured.The serum 25 OH-vitamin D level will be measured at baseline and 12 and 24 months; more frequent measurement will be performed, if indicated. Serum total and ionized calcium concentrations will be measured at baseline, 1, 3 months, and at 6-month intervals until month 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
General Endocrine Studies
Zeitfenster: Baseline (0), Month 12, Month 24
|
Serum thyroid function (T3, T4, & TSH; DiaSorin Inc. Stillwater, MN) will be determined by kit assay. |
Baseline (0), Month 12, Month 24
|
|
Additional variables by pQCT - Distal Tibia Microarchitecture
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to bone volume fraction (BV/TV)at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - Distal Tibia Microarchitecture
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to measure trabecular number (Tb.N) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - Distal Tibia Microarchitecture
Zeitfenster: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to measure trabecular thickness (Tb.Th)at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Serum ionized calcium concentration will be measured at baseline, months 1, 3, 6, 12, 18, and 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
24-hour urine calcium will be measured at baseline, months 1, 3, 6, 12, 18, and 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
25 OH-vitamin D levels (DiaSorin Inc. Stillwater, MN) will be measured at baseline and 12 and 24 months; more frequent measurement will be performed, if indicated. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
1,25 (OH)2-vitamin D level (Quest Diagnostics), will be measured at baseline and 12 and 24 months; more frequent measurement will be performed, if indicated. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Intact PTH level (ALPCO Diagnostics, Salem, NH) will be measured at Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
General Endocrine Studies
Zeitfenster: Baseline (0), Month 12, Month 24
|
Serum cortisol will be measured by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Zeitfenster: Baseline (0), Month 12, Month 24
|
Serum total testosterone (T) will be determined by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Zeitfenster: Baseline (0), Month 12, Month 24
|
Serum free testosterone (calculated from total T, albumin and SHBG) will be measured by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Zeitfenster: Baseline (0), Month 12, Month 24
|
Serum estradiol (E2) will be measured by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Zeitfenster: Baseline (0), Month 12, Month 24
|
Serum growth hormone (GH) will be measured by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Zeitfenster: Baseline (0), Month 12, Month 24
|
Serum insulin-like growth factor-1 (IGF-I) will be measured by kit assay (ALPCO Diagnostics, Salem, NH). |
Baseline (0), Month 12, Month 24
|
|
Biomarkers for Bone Formation
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Change in levels of bone alkaline phosphatase (MyBiosource, Inc., San Diego, CA) at baseline, month 1, month 3, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Biomarkers for Bone Formation
Zeitfenster: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Change in levels of propeptide of type 1 procollagen (P1NP) (MyBiosource, Inc., San Diego, CA) at baseline, month 1, month 3, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Christopher Cardozo, MD, James J. Peters Veterans Affairs Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Wunden und Verletzungen
- Trauma, Nervensystem
- Erkrankungen des Rückenmarks
- Verletzungen des Rückenmarks
- Aminosäuren, Peptide und Proteine
- Proteine
- Pharmazeutische Präparate
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Kristalloidlösungen
- Isotonische Lösungen
- Lösungen
- Denosumab
- Salzlösung
- Romosozumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- B3415-R
- BAU-19-66 (Andere Kennung: JJP VAMC Local IRB)
- 1600530 (Andere Kennung: JJP VAMC Local IRB)
- 5I01RX003415-06 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
There is not a plan to make IPD available.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .